Subscribe Now
Abiomed marked opening of its new $17 million Innovation Center on Friday, August 3 at the company’s global headquarters in Danvers. Eight patients who have benefitted from the Impella® heart pump were in attendance, joined by Dr. Melissa Wood, co-director of the Corrigan Women’s Heart Program at the Massachusetts General Hospital Heart Center and assistant professor of medicine at Harvard Medical School; Abiomed president, chairman, and CEO Michael Minogue; and Abiomed Innovation Center staff and research team to help cut the ribbon on the new center. The Impella® is the world’s smallest heart pump and it helps the heart rest and recover. The 29,800-square-foot Innovation Center will further enhance Abiomed’s research and engineering capabilities, while also boosting product development to benefit more patients. The Innovation Center is home to Abiomed’s engineering team and features five new laboratories – including blood and optical labs, software, mechanical and electrical labs, and a production line. The cCenter also includes six engineering scrum rooms and six video conference rooms that enable Abiomed to more easily connect with its team and other medical professionals from around the world.

Abiomed CEO Mike Minogue cuts the ribbon on the new center.

During the visit, patients had the opportunity to meet with the individual Abiomed employees who built the specific Impella® heart pump that contributed to their recovery. The patients visiting Abiomed reside in states across the country, including Ohio, Texas, Missouri, Michigan, North Carolina, Louisiana, and Georgia. Abiomed has been in Massachusetts since 1981, securing five FDA approvals and earning 317 patents, with another 311 pending. Abiomed is one of the fastest growing medical device companies in the nation and the only company with FDA approval for heart recovery. It has added 125 new employees at its Danvers headquarters over the past year. To learn more about the Impella platform of heart pumps, including their approved indications and important safety and risk information associated with the use of the devices, please visit: